Dysregulation of Antioxidant Mechanisms Contributes to Increased Oxidative Stress in Calcific Aortic Valvular Stenosis in Humans

Journal of the American College of Cardiology

Volumn 52, Issue 10, 2008, Pages 843-850

  Miller, Jordan D ^a   Chu, Yi ^a,b   Brooks, Robert M ^a   Richenbacher, Wayne E ^a   Peña Silva, Ricardo ^a   Heistad, Donald D ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

aortic valve; calcification; oxidative stress; stenosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CATALASE; CD68 ANTIGEN; COPPER ZINC SUPEROXIDE DISMUTASE; DICHLOROFLUORESCEIN; EXTRACELLULAR SUPEROXIDE DISMUTASE; HYDROETHIDINE; HYDROGEN PEROXIDE; ISOENZYME; LUCIGENIN; MANGANESE SUPEROXIDE DISMUTASE; NITRIC OXIDE SYNTHASE; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUPEROXIDE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR MSX1; TRANSCRIPTION FACTOR MSX2; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; AORTA VALVE CALCIFICATION; AORTA VALVE STENOSIS; ARTERY CALCIFICATION; ARTICLE; ATHEROSCLEROSIS; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE; HUMAN; HUMAN TISSUE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIOXIDANTS; AORTIC VALVE STENOSIS; ARTERIOSCLEROSIS; CALCINOSIS; CELL DIFFERENTIATION; DISEASE PROGRESSION; HUMANS; HYDROGEN PEROXIDE; INFLAMMATION; NADP; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; PILOT PROJECTS; RISK FACTORS; SUPEROXIDES;

EID: 49849089138     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.05.043     Document Type: Article

References (50)

1. Bonow R.O., Carabello B., de Leon A.C., et al. ACC/AHA guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). J Am Coll Cardiol 32 (1998) 1486-1588
2. Lindroos M., Kupari M., Valvanne J., Strandberg T., Heikkila J., and Tilvis R. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J 15 (1994) 865-870
3. Messika-Zeitoun D., Bielak L.F., Peyser P.A., et al. Aortic valve calcification: determinants and progression in the population. Arterioscler Thromb Vasc Biol 27 (2007) 642-648
4. Otto C.M., Kuusisto J., Reichenbach D.D., Gown A.M., and O'Brien K.D. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90 (1994) 844-853
5. Rajamannan N.M., Subramaniam M., Caira F., Stock S.R., and Spelsberg T.C. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 112 (2005) I229-I234
6. Yoshioka M., Yuasa S., Matsumura K., et al. Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis. Nat Med 12 (2006) 1151-1159
7. Jian B., Jones P.L., Li Q., Mohler III E.R., Schoen F.J., and Levy R.J. Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol 159 (2001) 321-327
8. Kaden J.J., Vocke D.C., Fischer C.S., et al. Expression and activity of matrix metalloproteinase-2 in calcific aortic stenosis. Z Kardiol 93 (2004) 124-130
9. Satta J., Oiva J., Salo T., et al. Evidence for an altered balance between matrix metalloproteinase-9 and its inhibitors in calcific aortic stenosis. Ann Thorac Surg 76 (2003) 681-688 discussion 688
10. Jian B., Narula N., Li Q.Y., Mohler E.R., and Levy R.J. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg 75 (2003) 457-465 discussion 465-6
11. Lee Y.S., and Chou Y.Y. Electron microscopic observations of apoptotic cells in various etiologies of human cardiovascular diseases. Chin Med J (Engl) 111 (1998) 428-432
12. Tanaka K., Sata M., Fukuda D., et al. Age-associated aortic stenosis in apolipoprotein E-deficient mice. J Am Coll Cardiol 46 (2005) 134-141
13. Mohler III E.R., Chawla M.K., Chang A.W., et al. Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis 8 (1999) 254-260
14. Rajamannan N.M., Subramaniam M., Rickard D., et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 107 (2003) 2181-2184
15. Mody N., Parhami F., Sarafian T.A., and Demer L.L. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med 31 (2001) 509-519
16. Fukai T., Galis Z.S., Meng X.P., Parthasarathy S., and Harrison D.G. Vascular expression of extracellular superoxide dismutase in atherosclerosis. J Clin Invest 101 (1998) 2101-2111
17. Weiss R.M., Ohashi M., Miller J.D., Young S.G., and Heistad D.D. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation 114 (2006) 2065-2069
18. Jacobi J., Kristal B., Chezar J., Shaul S.M., and Sela S. Exogenous superoxide mediates pro-oxidative, proinflammatory, and procoagulatory changes in primary endothelial cell cultures. Free Radic Biol Med 39 (2005) 1238-1248
19. Yoshii T., Iwai M., Li Z., et al. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Hypertens Res 29 (2006) 457-466
20. Levonen A.L., Inkala M., Heikura T., et al. Nrf2 gene transfer induces antioxidant enzymes and suppresses smooth muscle cell growth in vitro and reduces oxidative stress in rabbit aorta in vivo. Arterioscler Thromb Vasc Biol 27 (2007) 741-747
21. Ushio-Fukai M., Alexander R.W., Akers M., and Griendling K.K. p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. J Biol Chem 273 (1998) 15022-15029
22. Ohashi M., Runge M.S., Faraci F.M., and Heistad D.D. MnSOD deficiency increases endothelial dysfunction in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 26 (2006) 2331-2336
23. Schmidt T.S., and Alp N.J. Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease. Clin Sci (Lond) 113 (2007) 47-63
24. Zhang H., Luo Y., Zhang W., et al. Endothelial-specific expression of mitochondrial thioredoxin improves endothelial cell function and reduces atherosclerotic lesions. Am J Pathol 170 (2007) 1108-1120
25. Landmesser U., Dikalov S., Price S.R., et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111 (2003) 1201-1209
26. Milstien S., and Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun 263 (1999) 681-684
27. Zalba G., Fortuno A., Orbe J., et al. Phagocytic NADPH oxidase-dependent superoxide production stimulates matrix metalloproteinase-9: implications for human atherosclerosis. Arterioscler Thromb Vasc Biol 27 (2007) 587-593
28. Cucoranu I., Clempus R., Dikalova A., et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 97 (2005) 900-907
29. Dhar S.K., Xu Y., Chen Y., and St Clair D.K. Specificity protein 1-dependent p53-mediated suppression of human manganese superoxide dismutase gene expression. J Biol Chem 281 (2006) 21698-21709
30. Inoue I., Goto S., Matsunaga T., et al. The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 50 (2001) 3-11
31. Keen H.L., Ryan M.J., Beyer A., et al. Gene expression profiling of potential PPARgamma target genes in mouse aorta. Physiol Genomics 18 (2004) 33-42
32. Moura L.M., Ramos S.F., Zamorano J.L., et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 49 (2007) 554-561
33. Yang H., Roberts L.J., Shi M.J., et al. Retardation of atherosclerosis by overexpression of catalase or both Cu/Zn-superoxide dismutase and catalase in mice lacking apolipoprotein E. Circ Res 95 (2004) 1075-1081
34. Kobayashi S., Inoue N., Azumi H., et al. Expressional changes of the vascular antioxidant system in atherosclerotic coronary arteries. J Atheroscler Thromb 9 (2002) 184-190
35. 't Hoen P.A., Van der Lans C.A., Van Eck M., Bijsterbosch M.K., Van Berkel T.J., and Twisk J. Aorta of ApoE-deficient mice responds to atherogenic stimuli by a prelesional increase and subsequent decrease in the expression of antioxidant enzymes. Circ Res 93 (2003) 262-269
36. Barry-Lane P.A., Patterson C., van der Merwe M., et al. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J Clin Invest 108 (2001) 1513-1522
37. Kuzkaya N., Weissmann N., Harrison D.G., and Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 278 (2003) 22546-22554
38. Antoniades C., Shirodaria C., Crabtree M., et al. Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation. Circulation 116 (2007) 2851-2859
39. Lai C.F., Seshadri V., Huang K., et al. An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells. Circ Res 98 (2006) 1479-1489
40. Zhang Y.W., Yasui N., Ito K., et al. A RUNX2/PEBP2alpha A/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. Proc Natl Acad Sci U S A 97 (2000) 10549-10554
41. Steitz S.A., Speer M.Y., Curinga G., et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 89 (2001) 1147-1154
42. Shao J.S., Aly Z.A., Lai C.F., et al. Vascular Bmp Msx2 Wnt signaling and oxidative stress in arterial calcification. Ann N Y Acad Sci 1117 (2007) 40-50
43. Roy H., Bhardwaj S., Babu M., et al. VEGF-A, VEGF-D, VEGF receptor-1, VEGF receptor-2, NF-kappaB, and RAGE in atherosclerotic lesions of diabetic Watanabe heritable hyperlipidemic rabbits. Faseb J 20 (2006) 2159-2161
44. Moura L.M., Zamorano J., Perez-Oteyza C., Rocha-Gonclves F., and Rajamannan N.M. The role of statins in aortic stenosis. Myth or reality?. Rev Port Cardiol 26 (2007) 51-62
45. Rajamannan N.M. Reassessment of statins to retard the progression of aortic stenosis. Curr Cardiol Rep 9 (2007) 99-104
46. Rosenhek R., Rader F., Loho N., et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 110 (2004) 1291-1295
47. O'Brien K.D., Probstfield J.L., Caulfield M.T., et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med 165 (2005) 858-862
48. Cowell S.J., Newby D.E., Prescott R.J., et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352 (2005) 2389-2397
49. Nickenig G. Should angiotensin II receptor blockers and statins be combined?. Circulation 110 (2004) 1013-1020
50. Liberman M., Bassi E., Martinatti M.K., et al. Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification. Arterioscler Thromb Vasc Biol 28 (2008) 463-470